Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proteomics Clin Appl. 2008 Oct 1;2(10-11):1386-1402.

The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline.

Author information

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Abstract

The application of "omics" technologies to biological samples generates hundreds to thousands of biomarker candidates; however, a discouragingly small number make it through the pipeline to clinical use. This is in large part due to the incredible mismatch between the large numbers of biomarker candidates and the paucity of reliable assays and methods for validation studies. We desperately need a pipeline that relieves this bottleneck between biomarker discovery and validation. This paper reviews the requirements for technologies to adequately credential biomarker candidates for costly clinical validation and proposes methods and systems to verify biomarker candidates. Models involving pooling of clinical samples, where appropriate, are discussed. We conclude that current proteomic technologies are on the cusp of significantly affecting translation of molecular diagnostics into the clinic.

PMID:
20976028
[PubMed]
PMCID:
PMC2957839
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk